Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response to pathogen-associated molecular patterns stimulation in patients with IBS

Neurogastroenterology and Motility

Volumn 25, Issue 11, 2013, Pages

  Rodriguez Fandino O ^a   Hernandez Ruiz J ^a   Lopez Vidal Y ^a   Charua L ^b   Bandeh Moghaddam, H ^b   Minzoni, A ^c   Guzman C ^a   Schmulson, M ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Chemokines; CpG; Cytokines; Gut homing, residence, activated T cells; Innate immunity; Irritable bowel syndrome; Lipopolysaccharide; Peptidoglycan; Toll like receptors

Indexed keywords

ALPHA4 INTEGRIN; ALPHA4BETA7 INTEGRIN; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CPG ISLAND; ENTERITIS; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STIMULATION; SUPERNATANT; T LYMPHOCYTE;

CHEMOKINES; CPG; CYTOKINES; GUT HOMING, RESIDENCE, ACTIVATED T CELLS; INNATE IMMUNITY; IRRITABLE BOWEL SYNDROME; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; TOLL-LIKE RECEPTORS;

ADULT; ANTIGENS, CD28; CYTOKINES; ESCHERICHIA COLI; FEMALE; HUMANS; INTEGRINS; IRRITABLE BOWEL SYNDROME; MALE; RECEPTORS, CCR5; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84884982254     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12204     Document Type: Article

References (63)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721. e4.
2. Lopez-Colombo A, Morgan D, Bravo-Gonzalez D et al. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract 2012; 2012: 606174.
3. Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009; 43: 541-50.
4. Schmulson M, Pulido-London D, Rodriguez O et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747-53.
5. Chang L, Adeyemo M, Karagiannides I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-72.
6. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
7. Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 363-73.
8. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
9. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-76.
10. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
11. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-801.
12. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012; 18: 258-68.
13. O'Malley D, Quigley EM, Dinan TG et al. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun 2011; 25: 1333-41.
14. Antoni MH, Lutgendorf SK, Blomberg B et al. Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. Biol Psychiatry 2012; 71: 366-72.
15. Brint EK, MacSharry J, Fanning A et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-36.
16. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS ONE 2012; 7: e42777.
17. Ohman L, Lindmark AC, Isaksson S et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24: 398-405.
18. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
19. McKernan DP, Gaszner G, Quigley EM et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-52.
20. Ohman L, Isaksson S, Lindmark AC et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-12.
21. Ohman L, Lindmark AC, Isaksson S et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009; 21(644-50): e27.
22. Petrovic A, Alpdogan O, Willis LM et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2004; 103: 1542-7.
23. Agace W. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Lett 2010; 128: 21-3.
24. Liebregts T, Adam B, Bredack C et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106: 1089-98.
25. Kunkel EJ, Boisvert J, Murphy K et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 2002; 160: 347-55.
26. Kunkel EJ, Campbell DJ, Butcher EC. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 2003; 10: 313-23.
27. Johansson-Lindbom B, Agace WW. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 2007; 215: 226-42.
28. Jin B, Sun T, Yu XH et al. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol 2012; 2012: 836485.
29. + CD28- T cells in immune disorders. Trends Mol Med 2012; 18: 446-53.
30. Bryl E, Vallejo AN, Weyand CM et al. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001; 167: 3231-8.
31. Schmulson M, Ortiz O, Santiago-Lomeli M et al. Frequency of functional bowel disorders among healthy volunteers in Mexico City. Dig Dis 2006; 24: 342-7.
32. Thompson W, Longstreth G, Drossman DA. et al. C. Functional Bowel Disorders and D. Functional Abdominal Pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE and the Rome II Multinational Working Teams, eds. Rome II: The Functional Gastrointestinal Disorders, 2nd edn. McClean, VA: Degnon Associates Inc., 2000: 351-432.
33. Schmulson M, Lopez-Colombo A, Mendoza-Gomez A et al. The Rome III adult questionnaire in Spanish-Mexico has a low sensitivity for identifying IBS and higher sensitivity for uninvestigated dyspepsia. Gastroenterology 2012; 143: S-829.
34. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-83.
35. Remor E. Psychometric properties of a European Spanish version of the perceived stress scale (PSS). Span J Psychol 2006; 9: 86-93.
36. Ramirez MT, Hernandez RL. Factor structure of the Perceived Stress Scale (PSS) in a sample from Mexico. Span J Psychol 2007; 10: 199-206.
37. Godoy-Ramirez K, Franck K, Mahdavifar S et al. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J Immunol Methods 2004; 292: 1-15.
38. Villani AC, Lemire M, Thabane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-13.
39. Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043-55.
40. Wang Q, Dziarski R, Kirschning CJ et al. Micrococci and peptidoglycan activate TLR2->MyD88->IRAK->TRAF->NIK->IKK->NF-kappaB signal transduction pathway that induces transcription of interleukin-8. Infect Immun 2001; 69: 2270-6.
41. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-8.
42. Ghosh TK, Mickelson DJ, Solberg JC et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol 2007; 7: 1111-21.
43. + T cells. J Immunol 2005; 175: 1551-7.
44. + T cells via TLR4 complex. Eur J Immunol 2009; 39: 1564-72.
45. Germann A, Schulz JC, Kemp-Kamke B et al. Standardized serum-free cryomedia maintain peripheral blood mononuclear cell viability, recovery, and antigen-specific T-Cell response compared to fetal calf serum-based medium. Biopreserv Biobank 2011; 9: 229-36.
46. Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013; 62: 175-82.
47. Akiho H, Nakamura K. Daikenchuto ameliorates muscle hypercontractility in a murine T-cell-mediated persistent gut motor dysfunction model. Digestion 2011; 83: 173-9.
48. Castellani ML, De Lutiis MA, Toniato E et al. Impact of RANTES, MCP-1 and IL-8 in mast cells. J Biol Regul Homeost Agents 2010; 24: 1-6.
49. Cremon C, Carini G, Wang B et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-8.
50. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 2010; 126: 56-68.
51. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 2012; 12: 55-61.
52. Carvalho FA, Aitken JD, Vijay-Kumar M et al. Toll-like receptor-gut microbiota interactions: perturb at your own risk!. Annu Rev Physiol 2012; 74: 177-98.
53. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80.
54. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205-15.
55. Honda K, Takeda K. Regulatory mechanisms of immune responses to intestinal bacteria. Mucosal Immunol 2009; 2: 187-96.
56. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
57. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
58. Braak B, Klooker TK, Wouters MM et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012; 107: 715-26.
59. Langrish CL, Buddle JC, Thrasher AJ et al. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol 2002; 128: 118-23.
60. + T cells and their role in health and disease. Immunology 2011; 134: 17-32.
61. Kindt S, Van Oudenhove L, Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-98.
62. Merlo A, Calcaterra C, Menard S et al. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses. J Leukoc Biol 2007; 82: 509-18.
63. Ortiz O, Remes-Troche J, Valdovinos M et al. Frecuencia de factores desencadenantes extero e interoceptivos en la presentación inicial del síndrome de intestino irritable (SII) en un hospital de tercer nivel en México: Baja frecuencia de SII postinfeccioso? Rev Gastroenterol Mex 2003; 68: 98-9.